
SeeTreat will be at ASTRO 2026 booth 2913 in Boston, sharing our vision for the future of radiotherapy: enabling automated adaptive capabilities for any standard linac.



SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Read moreCome to Booth 2913 for SeeTreat booth talks from Radiation Oncology key opinions leaders and ART.1 users on how SeeTreat’s ART platform is streamlining adaptive and QA processes.
Professor Paul Keall (Medical Physics) and Professor Jarad Martin (Radiation Oncologist) will be providing demonstrations and presenting on how SeeTreat's ART pipeline is automating the end-to-end replan workflow.
ART.1 users will also be presenting on their experience on commissioning and rolling out SeeTreat products in their clinics and the real-world impact ART.1 is having at their centers.

Session Title: PQA 05: Physics
Session Time: 29 September 2026, 12:30pm -1:45pm
Author Block: Adam Mylonas, Nicholas Hardcastle, Shivani Kumar, Robert Finnegan, Brendan Whelan, Doan Trang Nguyen, Michael Jameson, Lars Mejnertsen


Dr Adam Mylonas will be presenting his abstract AAPM Guideline-Based Evaluation of Automated Dose Reconstruction using Cone Beam CT for Offline Adaptive Lung Radiation Therapy
